WO2009041026A1 - Inhibiteur de la production de cxcl10 - Google Patents

Inhibiteur de la production de cxcl10 Download PDF

Info

Publication number
WO2009041026A1
WO2009041026A1 PCT/JP2008/002634 JP2008002634W WO2009041026A1 WO 2009041026 A1 WO2009041026 A1 WO 2009041026A1 JP 2008002634 W JP2008002634 W JP 2008002634W WO 2009041026 A1 WO2009041026 A1 WO 2009041026A1
Authority
WO
WIPO (PCT)
Prior art keywords
cxcl10
production inhibitor
complement fragment
cxcl10 production
polypeptide
Prior art date
Application number
PCT/JP2008/002634
Other languages
English (en)
Japanese (ja)
Inventor
Yuji Takeda
Mayumi Hidaka
Noriyuki Shiobara
Katsuya Hiraishi
Nobuhito Kashiwagi
Original Assignee
Jimro Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jimro Co., Ltd. filed Critical Jimro Co., Ltd.
Publication of WO2009041026A1 publication Critical patent/WO2009041026A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention décrit un agent prophylactique/thérapeutique pour une maladie induite par la production excessive de CXCL10. L'invention décrit particulièrement un inhibiteur de la production de CXCL10 comportant, en tant qu'ingrédient actif, un fragment de complément choisi parmi iC3b et C4b, un polypeptide fonctionnellement équivalent au fragment de complément, ou un peptide partiel du fragment de complément ou du polypeptide.
PCT/JP2008/002634 2007-09-25 2008-09-24 Inhibiteur de la production de cxcl10 WO2009041026A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-247962 2007-09-25
JP2007247962A JP2010280569A (ja) 2007-09-25 2007-09-25 Ｃｘｃｌ１０産生抑制剤

Publications (1)

Publication Number Publication Date
WO2009041026A1 true WO2009041026A1 (fr) 2009-04-02

Family

ID=40510931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002634 WO2009041026A1 (fr) 2007-09-25 2008-09-24 Inhibiteur de la production de cxcl10

Country Status (2)

Country Link
JP (1) JP2010280569A (fr)
WO (1) WO2009041026A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006063A3 (fr) * 2012-07-02 2014-03-20 Medizinische Universität Wien Produit de séparation du complément c4d pour le traitement d'affections inflammatoires
JPWO2017014201A1 (ja) * 2015-07-17 2018-06-07 富士フイルム株式会社 含窒素複素環化合物
US10987349B2 (en) 2016-12-27 2021-04-27 Fujifilm Corporation Antitumor agent and bromodomain inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519479A (ja) * 2000-01-10 2003-06-24 イノジェネティックス・ナムローゼ・フェンノートシャップ ヒトおよび寄生体のオーファン受容体蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519479A (ja) * 2000-01-10 2003-06-24 イノジェネティックス・ナムローゼ・フェンノートシャップ ヒトおよび寄生体のオーファン受容体蛋白

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006063A3 (fr) * 2012-07-02 2014-03-20 Medizinische Universität Wien Produit de séparation du complément c4d pour le traitement d'affections inflammatoires
US9944685B2 (en) 2012-07-02 2018-04-17 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
US10358468B2 (en) 2012-07-02 2019-07-23 Medizinische Universität Wien Complement split product C4d for the treatment of inflammatory conditions
JPWO2017014201A1 (ja) * 2015-07-17 2018-06-07 富士フイルム株式会社 含窒素複素環化合物
US20190077761A1 (en) 2015-07-17 2019-03-14 Fujifilm Corporation Nitrogen-containing heterocyclic compound
EP3327004A4 (fr) * 2015-07-17 2019-03-27 Fujifilm Corporation Composé hétérocyclique contenant de l'azote
US10696637B2 (en) 2015-07-17 2020-06-30 Fujifilm Corporation Nitrogen-containing heterocyclic compound
US10987349B2 (en) 2016-12-27 2021-04-27 Fujifilm Corporation Antitumor agent and bromodomain inhibitor

Also Published As

Publication number Publication date
JP2010280569A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
WO2007143600A3 (fr) Inhibiteurs de la sheddase combinés avec des substances immunothérapeutiques se liant à cd30 destinés au traitement de maladies associées à cd30
WO2007095618A3 (fr) Utilisation de dérivés de sulfamide à noyau hétérocyclique benzofusionné pour le traitement de la migraine
WO2007017135A3 (fr) Procede de preparation d'olmesartane medoxomil
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
WO2009064388A3 (fr) Inhibiteurs de la méthionine aminopeptidase humaine 1 et procédés de traitement de troubles
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2007117971A3 (fr) Traitements de l'allergie oculaire
WO2007093183A3 (fr) Procede de traitement de maladies inflammatoires
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2009041787A3 (fr) Composition pharmaceutique comprenant des inhibiteurs de molécule d'adhérence cellulaire isolée de piper nigrum pour la prévention et le traitement de maladies inflammatoires
WO2007121088A3 (fr) Combinaisons d'agents thérapeutiques pour traiter un cancer
WO2009041663A1 (fr) Agent destiné à la prévention et/ou au traitement de maladies cutanées
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
WO2007030360A3 (fr) Inhibiteurs pi3k utiles dans le traitement de l'endometriose
WO2006108682A3 (fr) Substances et compositions pharmaceutiques destinees a inhiber les glyoxalases, et leur utilisation comme agents antifongiques
MX362830B (es) Agente terapeutico o profilactico para enfermedades del tracto biliar.
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
WO2009136997A3 (fr) Inhibiteurs des cathepsines l, b et s humaines
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
WO2009041786A3 (fr) Composition pharmaceutique comprenant des inhibiteurs de molécule d'adhérence cellulaire isolée de piper longum pour la prévention et le traitement de maladies inflammatoires
WO2009041026A1 (fr) Inhibiteur de la production de cxcl10
WO2007076318A3 (fr) Antagonistes de cxcr3 dérivés du camphre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834148

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08834148

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP